Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Im

General Practice Lady Lake, FL Doctor of Osteopathy

NPI 1922298454 CMS profile 41828

13767 N US Highway 441, Lady Lake, FL 32159

Open in the dashboard

General payments

$15,816

436 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Im of Lady Lake, FL is reported in the CMS Open Payments database as having received $15,816 across 436 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,744 42
2024 General $2,022 70
2023 General $2,130 80
2022 General $2,705 73
2021 General $3,526 83
2020 General $1,757 41
2019 General $1,932 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Im
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to John Im were reported at $1,744. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year John Im General Practice median Middle half National median
2019 $1,932 $107 $37–$285 $163
2020 $1,757 $75 $25–$213 $114
2021 $3,526 $93 $30–$272 $132
2022 $2,705 $103 $36–$279 $149
2023 $2,130 $106 $34–$276 $160
2024 $2,022 $114 $39–$290 $164
2025 $1,744 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $3,184 216 payments
  2. AstraZeneca Pharmaceuticals LP $2,740 123 payments
  3. E.R. Squibb & Sons, L.L.C. $1,233 11 payments
  4. Teva Pharmaceuticals USA, Inc. $1,201 12 payments
  5. Biohaven Pharmaceuticals, Inc. $1,183 10 payments
  6. SK Life Science, Inc. $800 7 payments
  7. Lundbeck LLC $771 7 payments
  8. Amgen Inc. $669 6 payments
  9. Sunovion Pharmaceuticals Inc. $593 6 payments
  10. AbbVie, Inc. $529 5 payments
  11. Other $2,914 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,816 436 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $2,851 197 payments
  2. NURTEC ODT $1,522 13 payments
  3. ZEPOSIA $1,389 13 payments
  4. BREZTRI $1,177 52 payments
  5. AIRSUPRA $1,063 43 payments
  6. FARXIGA $884 24 payments
  7. AIMOVIG $669 6 payments
  8. VYEPTI $664 6 payments
  9. AUSTEDO $579 5 payments
  10. XCOPRI $559 5 payments
  11. Other $5,164 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

3,520

Median for Emergency Medicine: 88

Drug cost

$72,755

Median for Emergency Medicine: $590

Branded share of claims

7.4%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 38 $28,873
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $10,767
Celecoxib Generic 195 $7,204
Prednisone Generic 1,250 $6,160
Azithromycin Generic 476 $2,668
Levofloxacin Generic 380 $2,191
Cephalexin Generic 212 $1,806
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 35 $1,587
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 130 $1,519
Clindamycin Hcl Generic 102 $1,310

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$315,194

Of which drugs: $3,574

Medicare patients

1,068

Average age 77

Services billed

16,926

636 women, 432 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 37%
Chronic kidney disease 31%
Diabetes 26%
Atrial fibrillation 23%
Depression 22%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 316 9,801 $2,251
Injection, methylprednisolone sodium succinate, up to 40 mg J2920 Office 218 260 $711
Injection, ketorolac tromethamine, per 15 mg J1885 Office 197 581 $311
Injection, ceftriaxone sodium, per 250 mg J0696 Office 69 248 $87
Injection, cefazolin sodium, 500 mg J0690 Office 46 74 $45

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $463
$463 — —
ZEPOSIA
  • E.R. Squibb & Sons, L.L.C. $330
$330 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $284
$284 17 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $251
$251 38 —
VYEPTI
  • Lundbeck LLC $223
$223 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

436 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record